SMC recommends VEOZA for moderate to severe menopausal vasomotor symptoms

RegulatoryapprovedVEOZAPositive

AI Analysis

Summary

The Scottish Medicines Consortium recommends VEOZA for moderate to severe menopausal vasomotor symptoms as a non-hormonal alternative for patients unsuitable for hormone replacement therapy.

Outcome Details

SMC (Scottish Medicines Consortium) recommendation for VEOZA as non-hormonal option for patients unsuitable for HRT

Importance:6/10

Sentiment:

0.70

regulatory approvalmenopausal healthnon-hormonalSMC recommendationVEOZA

Related Companies

$OPTN

Read the original article

Published by PharmaTimes on July 13, 2026 12:07 PM

Read Original